- Home
- Stem Cell Therapy Market
Global Stem Cell Therapy Market - Industry Trends and Forecast to 2029
- Published Date: September, 2022 | Report ID: CLS-466 | No of pages: 204 | Format:
The global stem cell therapy market is projected to register a substantial CAGR of 9.7% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029
Market Segmentation:
Global Stem Cell Therapy Market, Product Type (Bone Marrow Derived Mesenchymal Cells, Placental or Umbilical Stem Cell, Adipose Tissue Derived Mesenchymal Stem Cells, and Others), Type (Allogenic Stem Cell Therapy and Autologous Stem Cell Therapy), Application (Musculoskeletal Disorders, Acute Graft-Versus-Host Disease (AGVHD), Wounds and Injuries, Cardiovascular Diseases, Surgeries, Gastrointestinal Diseases, and Others), End User (Hospitals and Surgical Centers, Therapeutic Companies, Services Companies, and Others), Distribution Channel (Direct Tender, Third Party Distributors), Country (U.S., Canada, Italy, Belgium, Czech Republic, Germany, U.K., Spain, Hungary, Poland, South Korea, Japan and India, and Israel) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the global stem cell therapy market are:
The rise in prevalence and incidence of chronic diseases
High investments in research and development
Market Players:
Some of the major players operating in the global stem cell therapy market are:
Osiris Therapeutics, Inc. (A subsidiary of Smith+Nephew)
JCR Pharmaceuticals Co., Ltd
Orthofix Medical Inc.
MEDIPOST
Takeda Pharmaceutical Company Limited
CORESTEM, Inc.
PHARMICELL Co., Ltd.
STEMPEUTICS RESEARCH PVT LTD
ANTEROGEN.CO., LTD
Holostem Terapie Avanzate S.r.l.
U.S. Stem Cell, Inc
BrainStorm Cell Limited
Pluristem Inc.
International Stem Cell Corporation
Mesoblast Ltd
Athersys, Inc.
BioRestorative Therapies, Inc.
TABLE OF CONTENT
TABLE OF CONTENTS
1 INTRODUCTION 20
1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET DEFINITION 20
1.3 OVERVIEW OF THE GLOBAL STEM CELL THERAPY MARKET 21
1.4 CURRENCY AND PRICING 23
1.5 LIMITATIONS 23
1.6 MARKETS COVERED 23
2 GLOBAL STEM CELL THERAPY MARKET: SEGMENTATION 25
2.1 MARKETS COVERED 25
2.2 GEOGRAPHICAL SCOPE 26
2.3 YEARS CONSIDERED FOR THE STUDY 27
2.4 DBMR TRIPOD DATA VALIDATION MODEL 28
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 31
2.6 MULTIVARIATE MODELLING 32
2.7 PRODUCT SEGMENT LIFELINE CURVE 32
2.8 DBMR MARKET POSITION GRID 33
2.9 VENDOR SHARE ANALYSIS 35
2.10 MARKET END USER COVERAGE GRID 36
2.11 SECONDARY SOURCES 37
3 EXECUTIVE SUMMARY 38
4 PREMIUM INSIGHTS 42
4.1 PESTEL 44
4.2 PORTER'S FIVE FORCES MODEL 45
5 EPIDEMIOLOGY 46
6 PIPELINE ANALYSIS FOR THE GLOBAL STEM CELL THERAPY MARKET 47
7 GLOBAL STEM CELL THERAPY MARKET: REGULATIONS 48
8 MARKET OVERVIEW 51
8.1 DRIVERS 53
8.1.1 THE RISE IN PREVALENCE AND INCIDENCE OF CHRONIC DISEASES 53
8.1.2 RISE IN INVESTMENT IN RESEARCH AND DEVELOPMENT AND AVAILABILITY OF FUNDING FOR STEM CELL RESEARCH 54
8.1.3 GROWING BIOTECHNOLOGY SECTOR 55
8.1.4 RISE IN GMP CERTIFICATION APPROVALS FOR CELL THERAPY PRODUCTION FACILITIES 56
8.1.5 RISE IN CLINICAL TRIALS FOR STEM-CELL-BASED THERAPIES 56
8.2 RESTRAINTS 57
8.2.1 THE RISE IN COST OF STEM-CELL-BASED THERAPY RESEARCH 57
8.2.2 THE RISKS FACED WHILE UNDERGOING STEM CELL THERAPY 57
8.2.3 ETHICAL CONCERNS RELATED TO STEM CELL THERAPY RESEARCH 58
8.2.4 AVAILABILITY OF ALTERNATIVES 58
8.3 OPPORTUNITIES 58
8.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS 58
8.3.2 RISE IN HEALTHCARE EXPENDITURE 59
8.3.3 THE EMERGENCE OF INDUCED PLURIPOTENT STEM CELLS (IPSCS) 60
8.4 CHALLENGES 60
8.4.1 THE LACK OF SKILLED PROFESSIONALS REQUIRED FOR STEM CELL THERAPY 60
8.4.2 STRINGENT REGULATIONS 61
9 GLOBAL STEM CELL THERAPY MARKET, BY PRODUCT TYPE 63
9.1 OVERVIEW 64
9.2 BONE MARROW DERIVED MESENCHYMAL STEM CELLS 67
9.3 PLACENTAL/UMBILICAL STEM CELL 67
9.4 ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS 68
9.5 OTHERS 69
10 GLOBAL STEM CELL THERAPY MARKET, BY TYPE 71
10.1 OVERVIEW 72
10.2 ALLOGENEIC STEM CELL THERAPY 75
10.2.1 MUSCULOSKELETAL DISORDERS 76
10.2.2 WOUNDS AND INJURIES 76
10.2.3 ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) 76
10.2.4 SURGERIES 76
10.2.5 GASTROINTESTINAL DISEASES 76
10.2.6 OTHER APPLICATION 76
10.3 AUTOLOGOUS STEM CELL THERAPY 76
10.3.1 CARDIOVASCULAR DISEASES 78
10.3.2 GASTROINTESTINAL DISEASES 78
10.3.3 OTHER APPLICATION 78
11 GLOBAL STEM CELL THERAPY MARKET, BY APPLICATION 79
11.1 OVERVIEW 80
11.2 MUSCULOSKELETAL DISORDERS 82
11.3 WOUNDS AND INJURIES 83
11.4 ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) 84
11.5 SURGERIES 85
11.6 GASTROINTESTINAL DISEASES 86
11.7 CARDIOVASCULAR DISEASES 86
11.8 OTHER APPLICATION 87
12 GLOBAL STEM CELL THERAPY MARKET, BY END USER 89
12.1 OVERVIEW 90
12.2 HOSPITAL AND SURGICAL CENTERS 93
12.3 THERAPEUTIC COMPANIES 93
12.4 SERVICES COMPANIES 94
12.5 OTHERS 95
13 GLOBAL STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL 96
13.1 OVERVIEW 97
13.2 DIRECT TENDER 101
13.3 THIRD PARTY DISTRIBUTORS 101
14 GLOBAL STEM CELL THERAPY MARKET, BY REGION 103
14.1 OVERVIEW 104
14.2 NORTH AMERICA 109
14.2.1 U.S. 115
14.2.2 CANADA 117
14.3 ASIA-PACIFIC 119
14.3.1 SOUTH KOREA 125
14.3.2 JAPAN 127
14.3.3 INDIA 129
14.4 EUROPE 131
14.4.1 ITALY 137
14.4.2 BELGIUM 139
14.4.3 CZECH REPUBLIC 141
14.4.4 GERMANY 143
14.4.5 U.K. 145
14.4.6 SPAIN 147
14.4.7 HUNGARY 149
14.4.8 POLAND 151
14.5 MIDDLE EAST AND AFRICA 153
14.5.1 ISRAEL 159
14.6 SOUTH AMERICA 161
15 GLOBAL STEM CELL THERAPY MARKET: COMPANY LANDSCAPE 162
15.1 COMPANY SHARE ANALYSIS: GLOBAL 162
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 163
15.3 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 164
15.4 COMPANY SHARE ANALYSIS: EUROPE 165
16 SWOT ANALYSIS 166
17 COMPANY PROFILE 167
17.1 OSIRIS THERAPEUTICS, INC. (A SUBSIDIARY OF SMITH+NEPHEW) (2021) 167
17.1.1 COMPANY SNAPSHOT 167
17.1.2 REVENUE ANALYSIS 167
17.1.3 COMPANY SHARE ANALYSIS 168
17.1.4 PRODUCT PORTFOLIO 168
17.1.5 RECENT DEVELOPMENT 168
17.2 JCR PHARMACEUTICALS CO., LTD ( (2021) 169
17.2.1 COMPANY SNAPSHOT 169
17.2.2 REVENUE ANALYSIS 169
17.2.3 COMPANY SHARE ANALYSIS 170
17.2.4 PRODUCT PORTFOLIO 170
17.2.5 RECENT DEVELOPMENTS 170
17.3 ORTHOFIX MEDICAL INC. (2021) 171
17.3.1 COMPANY SNAPSHOT 171
17.3.2 REVENUE ANALYSIS 171
17.3.3 COMPANY SHARE ANALYSIS 172
17.3.4 PRODUCT PORTFOLIO 172
17.3.5 RECENT DEVELOPMENTS 172
17.4 MEDIPOST (2021) 174
17.4.1 COMPANY SNAPSHOT 174
17.4.2 REVENUE ANALYSIS 174
17.4.3 COMPANY SHARE ANALYSIS 175
17.4.4 PRODUCT PORTFOLIO 175
17.4.5 RECENT DEVELOPMENTS 175
17.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED (2021) 177
17.5.1 COMPANY SNAPSHOT 177
17.5.2 REVENUE ANALYSIS 177
17.5.3 COMPANY SHARE ANALYSIS 178
17.5.4 PRODUCT PORTFOLIO 178
17.5.5 RECENT DEVELOPMENT 178
17.6 CORESTEM, INC. (2021) 179
17.6.1 COMPANY SNAPSHOT 179
17.6.2 REVENUE ANALYSIS 179
17.6.3 PRODUCT PORTFOLIO 180
17.6.4 RECENT DEVELOPMENT 180
17.7 PHARMICELL CO., LTD. (2021) 181
17.7.1 COMPANY SNAPSHOT 181
17.7.2 PRODUCT PORTFOLIO 181
17.7.3 RECENT DEVELOPMENTS 181
17.8 ANTEROGEN.CO., LTD (2021) 182
17.8.1 COMPANY SNAPSHOT 182
17.8.2 PRODUCT PORTFOLIO 182
17.8.3 RECENT DEVELOPMENTS 182
17.9 ATHERSYS, INC.(2021) 183
17.9.1 COMPANY SNAPSHOT 183
17.9.2 REVENUE ANALYSIS 183
17.9.3 PRODUCT PORTFOLIO 184
17.9.4 RECENT DEVELOPMENTS 184
17.10 BRAINSTORM CELL LIMITED (2021) 185
17.10.1 COMPANY SNAPSHOT 185
17.10.2 PRODUCT PORTFOLIO 185
17.10.3 RECENT DEVELOPMENTS 185
17.11 BIORESTORATIVE THERAPIES, INC. (2021) 187
17.11.1 COMPANY SNAPSHOT 187
17.11.2 REVENUE ANALYSIS 187
17.11.3 PRODUCT PORTFOLIO 188
17.11.4 RECENT DEVELOPMENTS 188
17.12 HOLOSTEM TERAPIE AVANZATE S.R.L. (2021) 189
17.12.1 COMPANY SNAPSHOT 189
17.12.2 PRODUCT PORTFOLIO 189
17.12.3 RECENT DEVELOPMENTS 189
17.13 INTERNATIONAL STEMCELL CORPORATION (2021) 191
17.13.1 COMPANY SNAPSHOT 191
17.13.2 REVENUE ANALYSIS 191
17.13.3 PRODUCT PORTFOLIO 192
17.13.4 RECENT DEVELOPMENT 192
17.14 MESOBLAST LTD (2021) 193
17.14.1 COMPANY SNAPSHOT 193
17.14.2 REVENUE ANALYSIS 193
17.14.3 PRODUCT PORTFOLIO 194
17.14.4 RECENT DEVELOPMENTS 194
17.15 PLURISTEM INC.(2021) 195
17.15.1 COMPANY SNAPSHOT 195
17.15.2 REVENUE ANALYSIS 195
17.15.3 PRODUCT PORTFOLIO 196
17.15.4 RECENT DEVELOPMENT 196
17.16 STEMPEUTICS RESEARCH PVT LTD 197
17.16.1 COMPANY SNAPSHOT 197
17.16.2 PRODUCT PORTFOLIO 197
17.16.3 RECENT DEVELOPMENTS 197
17.17 U.S. STEM CELL, INC. (2021) 199
17.17.1 COMPANY SNAPSHOT 199
17.17.2 REVENUE ANALYSIS 199
17.17.3 PRODUCT PORTFOLIO 200
17.17.4 RECENT DEVELOPMENT 200
18 QUESTIONNAIRE 201
19 RELATED REPORTS 204
Segmentation
Short Description
Global Stem Cell Therapy Market, Product Type (Bone Marrow Derived Mesenchymal Cells, Placental or Umbilical Stem Cell, Adipose Tissue Derived Mesenchymal Stem Cells, and Others), Type (Allogenic Stem Cell Therapy and Autologous Stem Cell Therapy), Application (Musculoskeletal Disorders, Acute Graft-Versus-Host Disease (AGVHD), Wounds and Injuries, Cardiovascular Diseases, Surgeries, Gastrointestinal Diseases, and Others), End User (Hospitals and Surgical Centers, Therapeutic Companies, Services Companies, and Others), Distribution Channel (Direct Tender, Third Party Distributors), Country (U.S., Canada, Italy, Belgium, Czech Republic, Germany, U.K., Spain, Hungary and Poland, South Korea, Japan and India, and Israel) Industry Trends and Forecast to 2029
Market Definition:
Stem cells are the body's initial materials from which all other cells with specialized functions are generated. Under the right conditions in the body or a laboratory, stem cells divide to form more cells called daughter cells. The daughter cells become new stem cells or specialized cells (differentiation) with a more specific function, such as blood cells, brain cells, heart muscle cells, or bone cells. Much interest in stem cells has brought interest among the research scientists. Understanding how a disease develops and occurs by using stem cells, generating healthy cells to replace cells, and testing novel drug safety and efficacy are the scientific reasons why stem cell therapeutics are used.
Stem cell therapy promotes dysfunctional or injured tissue repair response using stem cells or their derivatives. It is the next chapter in organ transplantation and uses cells instead of donor organs, which are limited in supply. The adult stem cells, such as adipose tissue-derived mesenchymal stem cells, bone marrow-derived mesenchymal stem cells, and placental or umbilical stem cells, are found in small numbers in most tissues. The embryonic stem cells originate from embryos, which are three to five days old. Emerging indications indicate that adult stem cells may be able to create various types of cells.
Market Segmentation:
The global stem cell therapy market is categorized into product type, type, applications, end user, and distribution channel.
On the basis of product type, the global stem cell therapy market is segmented into placental or umbilical stem cell, bone marrow derived mesenchymal cells, adipose tissue derived mesenchymal stem cells, and others
On the basis of type, the global stem cell therapy market is segmented into allogenic stem cell therapy and autologous stem cell therapy
On the basis of application, the global stem cell therapy market is segmented into musculoskeletal disorders, wounds and injuries, acute graft-versus-host disease (AGVHD), surgeries, gastrointestinal diseases, cardiovascular diseases, and others
On the basis of end user, the global stem cell therapy market is segmented into hospitals and surgical centers, therapeutic companies, services companies, and others
On the basis of distribution channel, the global stem cell therapy market is segmented into direct tenders and third party distributor
Market Players
Some of the major players operating in the global stem cell therapy market are:
Osiris Therapeutics, Inc. (A subsidiary of Smith+Nephew)
JCR Pharmaceuticals Co., Ltd
Orthofix Medical Inc.
MEDIPOST
Takeda Pharmaceutical Company Limited
CORESTEM, Inc.
PHARMICELL Co., Ltd.
STEMPEUTICS RESEARCH PVT LTD
ANTEROGEN.CO., LTD
Holostem Terapie Avanzate S.r.l.
U.S. Stem Cell, Inc
BrainStorm Cell Limited
Pluristem Inc.
International Stem Cell Corporation
Mesoblast Ltd
Athersys, Inc.
BioRestorative Therapies, Inc.
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.